Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-31 02:01 UTC

BIOMED PULSE

Monday, 31 August 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the DRC has now spread from 54 to 60 health zones across six provinces, making it the largest Ebola outbreak ever recorded in that country — the situation is intensifying and tone is grave.

Food safety alerts are multiplying in the U.S. with simultaneous active outbreaks of Salmonella, E. coli, and Listeria; longevity science offers cautious optimism on senescence and testosterone biology.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC) — HISTORIC SCALE

  • As of 28 August 2026, the Bundibugyo virus disease (BVD) outbreak has spread from 54 to 60 health zones, now touching six of the DRC's 26 provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO's 15 August DON described the epidemic as "the largest Ebola outbreak ever reported" in the DRC, expanding faster than any previous Ebola outbreak, with sustained community transmission as the dominant driver. [2]
  • The most recent WHO count (DON-613, 15 July) tallied 2,124 confirmed cases and 828 deaths from the DRC alone, with cross-border transmission to Uganda confirmed since May; the 28 August update adds six new health zones to that toll. [3][1]
  • Six additional health zones reporting cases in the latest update signal active, uncontrolled geographic spread despite ongoing CDC airport screening at Dulles and Atlanta. [1]

ALFALFA SPROUT DUAL OUTBREAK — E. COLI AND SALMONELLA

  • CDC warned on 21 August 2026 of a multistate outbreak simultaneously linked to recalled alfalfa sprouts involving both E. coli and Salmonella; consumers should not eat the recalled product. [4]

SALMONELLA — RECALLED EGGS, NEARLY 100 ILL

  • As of 28 August 2026, 95 people across 14 states have been sickened with the same Salmonella strain linked to recalled eggs; CDC urges consumers to discard recalled product immediately. [5]

SALMONELLA — JALAPEÑOS

  • CDC posted a multistate food safety alert on 5 August 2026 linking a Salmonella outbreak to jalapeños; the number of affected states was not specified in the summary. [6]

CYCLOSPORA — TACO BELL SHREDDED ICEBERG LETTUCE

  • As of 17 July 2026, 1,644 people were sick across at least five states (later expanded to four additional states as of 24 July) with Cyclospora infections traced to shredded iceberg lettuce served at Taco Bell locations. [7][8]

WEST NILE VIRUS — RECORD EARLY SEASON

  • CDC reported on 1 July 2026 that the 2026 West Nile season is tracking record early case counts; the agency urged mosquito bite prevention over the America's 250th anniversary holiday weekend. [9]

MEASLES — BANGLADESH NATIONWIDE SURGE

  • WHO reported on 23 April 2026 that Bangladesh notified 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts and all eight divisions. [10]

NIPAH VIRUS — INDIA (KERALA)

  • On 11 June 2026, Kerala State health authorities confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male presented with neurological symptoms after onset on 30 May.

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • As of the fifth WHO DON (2 July 2026), the Andes hantavirus (ANDV) outbreak linked to cruise ship M/V Hondius, first notified 2 May, remains under active monitoring across multiple countries with ongoing case investigation.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy's IHR focal point notified WHO on 21 March 2026 of a human H9N2 case in an adult male who had returned from Senegal; next-generation sequencing confirmed influenza A(H9N2).

YELLOW FEVER — GLOBAL

  • WHO reported on 24 June 2026 that from 1 January to 26 May 2026, six countries reported 79 human yellow fever infections, with sustained transmission activity carrying over from an elevated 2025 Americas season.

🧬 LONGEVITY & AGING

TESTOSTERONE — LONGEVITY TRADE-OFF DECODED BY MENDELIAN RANDOMIZATION

  • A Mendelian randomization study published in Aging Male (17 August 2026) found that testosterone exerts measurable trade-offs between longevity and reproductive fitness, suggesting the hormone's effects on lifespan are not straightforwardly beneficial or harmful but context-dependent.
  • A companion international expert consensus in Aging Male (26 August 2026), authored by David et al. including researchers Hackett, Jones, Khera, Traish, and Zitzmann, offers primary-care clinicians a framework for managing testosterone deficiency in aging men.

SENESCENCE IN OSTEOARTHRITIS — DUAL ANTIOXIDANT AND EPIGENETIC ATTACK

  • A study published in Bioactive Materials (31 July 2026) by An et al. demonstrated that combining antioxidant and epigenetic interventions disrupts the self-perpetuating senescence cycle in osteoarthritis joint tissue, opening a potential therapeutic avenue for a major age-related disease.

BONE STEM CELLS AND AGING FRACTURE REPAIR

  • Hu et al., publishing in Bioactive Materials (4 August 2026), showed that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is directly associated with the impaired fracture healing seen in aged mice, identifying EGFR signaling as a target for improving bone repair in older adults.

SENILE OSTEOPOROSIS — PUNICALAGIN AND THE NRF2/HO-1 PATHWAY

  • Wang et al. in Regenerative Therapy (25 July 2026) found that punicalagin, a polyphenol from pomegranate, alleviates age-related osteoporosis by inhibiting senescence of bone mesenchymal stem cells through the NRF2/HO-1 antioxidant pathway in a preclinical model.

HEAT TOLERANCE IN AN AGING WORLD — LANCET PLANETARY HEALTH MODELLING

  • Kong et al. in Lancet Planetary Health (published ahead of print) used global projection modelling to show that the combination of climate warming and population aging will push growing numbers of people beyond human physiological heat tolerance limits, with older adults disproportionately at risk.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • Lääti et al. in Blood Pressure (7 August 2026), drawing on two Finnish generational cohorts born 20 years apart, found an association between positive life orientation and lower blood pressure in older adults, suggesting psychological outlook has measurable cardiovascular relevance across generations.

SLEEP DURATION AND HYPERTENSION IN OLDER ADULTS

  • Wang et al. in Blood Pressure (16 August 2026) published a cross-sectional study associating abnormal sleep duration with higher hypertension prevalence in older adults, adding sleep architecture to the list of modifiable aging-related cardiovascular risk factors.

DEPRESCRIBING TRIALS — A CALL FOR RATIONALE-FIRST DESIGN

  • Two commentaries in Lancet Healthy Longevity (Hwang, Boockvar, and Steinman; and Van der Linden) argue that deprescribing trials in older adults need a rationale-first framework before selecting trial design, warning that poorly designed trials will not yield actionable guidance for polypharmacy reduction in aging populations.

METABOLIC LIVER DISEASE — LYSOSOMAL AMPK ACTIVATION VIA UDP-GlcNAc NANOSHEETS

  • Zhu et al. in Bioactive Materials (12 July 2026) reported that UDP-GlcNAc nanosheets targeting ROAM1 selectively activate lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) in a preclinical model — a mechanistically novel approach to a condition strongly linked to aging and metabolic syndrome.

💊 NEW CURES & APPROVALS

IMAAVY (NIPOCALIMAB-AAHU) — JANSSEN BIOTECH

  • openFDA records a supplemental approval (SUPPL AP) action for IMAAVY (nipocalimab-aahu), a neonatal Fc receptor (FcRn) blocker by Janssen Biotech; nipocalimab reduces circulating IgG antibodies and has been studied in immune-mediated diseases including generalized myasthenia gravis and hemolytic disease of the fetus and newborn.

TEVIMBRA (TISLELIZUMAB-JSGR) — BEIGENE

  • openFDA records a supplemental approval action for TEVIMBRA (tislelizumab-jsgr), BeiGene's anti-PD-1 immune checkpoint inhibitor, indicating an expanded or updated oncology indication.

ZIIHERA (ZANIDATAMAB-HRII) — JAZZ PHARMACEUTICALS

  • openFDA records a supplemental approval for ZIIHERA (zanidatamab-hrii) from Jazz Pharmaceuticals, a HER2-targeted bispecific antibody with activity in biliary tract and gastroesophageal cancers.

ZEPBOUND (TIRZEPATIDE) — ELI LILLY AND COMPANY

  • openFDA records a supplemental approval action for ZEPBOUND (tirzepatide), Eli Lilly's dual GIP/GLP-1 receptor agonist approved for obesity; the supplement may reflect an expanded indication or new formulation.

TIVICAY / TIVICAY PD (DOLUTEGRAVIR SODIUM) — VIIV HEALTHCARE

  • openFDA records supplemental approval actions for both TIVICAY and TIVICAY PD (dolutegravir sodium), ViiV Healthcare's integrase strand transfer inhibitor used in HIV treatment across adult and pediatric populations.

BENLYSTA (BELIMUMAB) — GLAXOSMITHKLINE LLC

  • openFDA records a supplemental approval for BENLYSTA (belimumab), GSK's BLyS-targeting biologic for systemic lupus erythematosus and lupus nephritis.

🧪 CLINICAL TRIALS

SELTOREXANT FOR MAJOR DEPRESSIVE DISORDER WITH INSOMNIA (PHASE 3)

  • A Phase 3 trial (NCT06559306, updated 28 August 2026) is evaluating seltorexant, an orexin-1/2 receptor antagonist, as adjunctive therapy to antidepressants in adult and elderly participants with major depressive disorder and comorbid insomnia symptoms; the study assesses both short-term efficacy and maintenance effects versus placebo.

PROTEIN, BLUEBERRIES, AND EXERCISE FOR CARDIOVASCULAR HEALTH AND FRAILTY IN OLDER ADULTS

  • Trial NCT06693271 (updated 28 August 2026) is investigating the combined effects of protein supplementation, blueberry consumption, and structured exercise on cardiovascular health and frailty markers in older Nova Scotians, targeting the intersection of nutrition, physical activity, and accelerated aging.

QUERCETIN FOR GLUCOSE ABSORPTION IN OBESITY AND TYPE 2 DIABETES

  • Trial NCT00065676 (updated 28 August 2026) is examining whether quercetin, a naturally occurring polyphenol, alters intestinal glucose absorption in volunteers with obesity or obesity combined with type 2 diabetes — both conditions central to metabolic aging.

FOSTAMATINIB FOR LUNG TRANSPLANT REJECTION (SIMILAR TRIAL)

  • The SIMILAR trial (NCT06948097, updated 28 August 2026) is evaluating fostamatinib, a Syk kinase inhibitor, for safety and tolerability in lung transplant patients who have developed donor-specific antibodies — a population with substantially reduced post-transplant longevity.

OLDER ADULTS' RECOVERY DYNAMICS AFTER CARDIAC SURGERY

  • Trial NCT07793708 (registered 28 August 2026) is prospectively studying how older adults recover physiologically after cardiac surgery, with a focus on delirium, organ dysfunction, and delayed functional recovery — outcomes that increase sharply with aging and frailty.

N-ACETYL-D-MANNOSAMINE (ManNAc) IN PODOCYTE KIDNEY DISEASES (PHASE 2)

  • An open-label Phase 2 trial (NCT06664814, updated 28 August 2026) is testing ManNAc in patients with focal segmental glomerulosclerosis, minimal change disease, and membranous nephropathy — podocyte diseases whose prevalence rises with age.

📢 PUBLIC HEALTH

LISTERIA — ONGOING OUTBREAK, DELI MEATS AND PREPARED FOODS

  • The longstanding Listeria monocytogenes outbreak linked to deli meats and expanded to prepared foods is still active; CDC urges consumers to check refrigerators and freezers for any recalled products and discard them immediately without eating.

KINDERGARTEN VACCINATION RATES

  • CDC data released 17 August 2026 show kindergarten vaccination coverage remains high nationally, though a 0.1 percentage point decline in coverage was recorded — a signal CDC is monitoring given ongoing measles transmission.

DRUG OVERDOSE DEATHS — CONTINUED DECLINE

  • CDC's May 2025 provisional data showed a 27% decrease in U.S. drug overdose deaths in 2024, the second consecutive year of significant decline after a nearly 24% drop reported in February 2025.

CDC BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 2026, bolstering early-warning capacity for novel pathogen detection at U.S. ports of entry.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Outbreak linked to alfalfa sprouts; people sickened with <em>E… — CDC Newsroom
  5. Nearly 100 people sick in <em>Salmonella </em>outbreak linked … — CDC Newsroom
  6. CDC warns of <em>Salmonella</em> outbreak linked to jalapeños — CDC Newsroom
  7. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom
  8. Cyclospora outbreak linked to iceberg lettuce expanded to four… — CDC Newsroom
  9. CDC Encourages Americans to Stay Mosquito Bite-Free during Ame… — CDC Newsroom
  10. Measles - Bangladesh — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260831-02-v62 · 2026-08-31 02:01 UTC · pulse.uzylab.com

Read next